{
  "id": "mhgap#screening_cues_5ae20015",
  "content": "16. Monitoring & Evaluation\nMonitoring and Evaluation (M&E) can provide information about Evaluate the mhGAP-IG implementation process, identify There are four main groups of medications that target priority\nwhether a programme is making a difference and for whom; it can successes as well as needs for improvement and update the MNS conditions mentioned in this guide:\nidentify programme areas that are on target or aspects of a pro- situation analysis.\nantipsychotics for psychotic disorders;\ngramme that need to be adjusted. Information gained from M&E\ncan demonstrate to programme implementers and funders that drugs used in mood disorders (depressive or bipolar);\nIn addition to the six actions described above, there are three\ntheir investments are paying off. M&E provides vital information\ncontinuous activities that form an essential part of mhGAP-IG anticonvulsants/antiepileptics;\nfor learning from past experiences, improving service delivery,\nimplementation. These are described in the sections below.\nplanning, resource allocation and demonstrating results as part medications used for management of substance withdrawal,\nof accountability to key stakeholders. The phrase, “what gets intoxication or dependence .\nA. PROVISION OF TREATMENT AND CARE:\nmeasured gets done,” summarises the importance of monitoring\nThe experiences of many countries demonstrate that",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues 16. Monitoring & Evaluation\nMonitoring and Evaluation (M&E) can provide information about Evaluate the mhGAP-IG implementation process, identify There are four main groups of medications that target priority\nwhether a programme is making a difference and for whom; it can successes as well as needs for improvement and update the MNS conditions mentioned in this guide:\nidentify programme areas that are on target or aspects of a pro- situation analysis.\nantipsychotics for psychotic disorders;\ngramme that need to be adjusted. Information gained from M&E\ncan demonstrate to programme implementers and funders that drugs used in mood disorders (depressive or bipolar);\nIn addition to the six actions described above, there are three\ntheir investments are paying off. M&E provides vital information\ncontinuous activities that form an essential part of mhGAP-IG anticonvulsants/antiepileptics;\nfor learning from past experiences, improving service delivery,\nimplementation. These are described in the sections below.\nplanning, resource allocation and demonstrating results as part medications used for management of substance withdrawal,\nof accountability to key stakeholders. The phrase, “what gets intoxication or dependence .\nA. PROVISION OF TREATMENT AND CARE:\nmeasured gets done,” summarises the importance of monitoring\nThe experiences of many countries demonstrate that 16. monitoring & evaluation\nmonitoring and evaluation (m&e) can provide information about evaluate the mhgap-ig implementation process, identify there are four main groups of medications that target priority\nwhether a pr..."
}